Eli Lilly (LLY) Stock Crushes Earnings as Weight Loss Drug Sales Jump 184%

TLDR Eli Lilly reported Q3 earnings of $7.02 per share and revenue of $17.60 billion, both beating Wall Street estimates by wide margins. The company raised its full-year 2025 revenue guidance to $63-63.5 billion and adjusted earnings to $23-23.70 per share. Mounjaro diabetes treatment brought in $6.52 billion in Q3 revenue, up 109% year-over-year, while [...]

The post Eli Lilly (LLY) Stock Crushes Earnings as Weight Loss Drug Sales Jump 184% appeared first on Blockonomi.